Medical specialists from Netherlands tagged as investigators in clinical trials studying Usher Syndromes

Total 2 results

Erwin van Wijk, PhD
Seen in:
- Nijmegen, Radboud University Nijmegen Medical Centre, Dept. Otorhinolaryngology
Trials:
- NCT01954953 (Principal Investigator)
Conditions:
- Usher Syndrome
Ingeborgh van den Born
Seen in:
- Rotterdam, Stichting Oogziekenhuis Rotterdam
Trials:
- NCT03814499 (Principal Investigator)
Conditions:
- Usher Syndrome, Type 1B

Clinical Trials on Usher Syndromes

Fondazione Telethon

Unknown

Natural History Study in Subjects With Usher Syndrome

Usher Syndrome, Type 1B

Italy, Netherlands, Spain
Neurotech Pharmaceuticals
University of California, San Francisco

Completed

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Retinitis Pigmentosa | Usher Syndrome Type 2 | Usher Syndrome Type 3

United States
Sanofi

Terminated

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Retinitis Pigmentosa | Usher Syndrome

United States, France
Jaeb Center for Health Research
Foundation Fighting Blindness

Active, not recruiting

Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A)

Usher Syndrome, Type 2A | Retinitis Pigmentosa 39

United States, Canada, France, Germany, Netherlands, United Kingdom
Radboud University Medical Center
Stichting Ushersyndroom

Active, not recruiting

Characterizing Rate of Progression in USHer Syndrome (CRUSH) Study (CRUSH)

Retinitis Pigmentosa | Usher Syndrome, Type 2A | USH2A

Netherlands
ProQR Therapeutics

Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)

Retinitis Pigmentosa | Usher Syndrome Type 2

United States, Canada, France
Sanofi

Active, not recruiting

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Usher's Syndrome

United States, France
ProQR Therapeutics

Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Canada, France
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom

Medical specialists from Netherlands tagged as investigators in clinical trials studying Usher Syndromes

Clinical Trials on Usher Syndromes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations